Development of a novel nomogram to predict hemorrhagic transformation following endovascular treatment in patients with acute ischemic stroke

开发一种新型列线图,用于预测急性缺血性卒中患者血管内治疗后出血性转化

阅读:1

Abstract

BACKGROUND: Hemorrhagic transformation (HT) is a critical complication of endovascular therapy (EVT) in acute ischemic stroke (AIS), significantly worsening patient outcomes. Although various risk factors have been identified, existing predictive models often fail to account for the multimodal nature of EVT and the complex interplay of clinical, imaging, and laboratory variables. OBJECTIVE: This study aimed to develop and validate a nomogram-based predictive model to estimate the risk of HT in AIS patients undergoing EVT, incorporating clinical, imaging, and laboratory data to provide a comprehensive risk assessment. METHODS: A retrospective analysis was performed on 154 AIS patients who underwent EVT at a single center between 2018 and 2023. The least absolute shrinkage and selection and operator (LASSO) and multivariate logistic regression were used to identify the independent predictors of HT. A nomogram was constructed and evaluated using the area under the receiver operating characteristic curve (AUC-ROC), calibration curves, and decision curve analysis (DCA). RESULTS: Among the 154 patients, 34.4% experienced HT. The nomogram demonstrated excellent discriminatory ability, with an AUC-ROC of 0.82 (95% CI: 0.752-0.888), and strong calibration, as indicated by calibration curves. DCA confirmed the model's clinical utility when the threshold probability was <0.8. Six independent prediction factors of HT were identified: atrial fibrillation (OR: 6.152), albumin (OR: 1.145), baseline NIHSS score (OR: 1.081), diastolic blood pressure (OR: 1.057), Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Classification (TOAST_2, cardioembolic stroke subtype, OR: 0.201), and the location of obstructed blood vessel_5 (basilar artery occlusion, OR: 0.081). CONCLUSION: The developed nomogram provides an accurate, individualized risk assessment of HT in AIS patients undergoing EVT. This tool enables personalized risk stratification, aiding clinicians in optimizing treatment strategies and improving patient outcomes. Further multicenter validation is warranted to generalize these findings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。